Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 427-440

  Stucki, David M ^a   Ruegsegger, Céline ^a   Steiner, Silvio ^a   Radecke, Julika ^a,b   Murphy, Michael P ^c   Zuber, Benoît ^b   Saxena, Smita ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Antioxidant MitoQ; Electron transport chain (ETC) activities; Mitochondria; Neurodegeneration; Oxidative stress; Purkinje cells; Spinocerebellar ataxia type 1

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ANTIOXIDANT; ATAXIN 1; CALCIUM BINDING PROTEIN; CHAPERONIN 60; CYTOCHROME C; CYTOCHROME C OXIDASE; MESYLIC ACID; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOQUINONE MESYLATE; MULTIENZYME COMPLEX; OXIDOREDUCTASE; PEROXIREDOXIN 3; PROTEOME; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; 10-(6'-UBIQUINONYL)DECYLTRIPHENYLPHOSPHONIUM BROMIDE; ORGANOPHOSPHORUS COMPOUND; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL AGING; CELL LOSS; COLORIMETRY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOWN SYNDROME; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MOTOR COORDINATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PURKINJE CELL; RESPIRATORY CHAIN; SCANNING ELECTRON MICROSCOPY; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR DEGENERATION; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; DISEASE EXACERBATION; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; PRECLINICAL STUDY;

ANIMALS; ANTIOXIDANTS; DISEASE PROGRESSION; DNA DAMAGE; DNA, MITOCHONDRIAL; DRUG EVALUATION, PRECLINICAL; MICE, INBRED C57BL; MITOCHONDRIA; ORGANOPHOSPHORUS COMPOUNDS; OXIDATIVE STRESS; PROTEOME; SPINOCEREBELLAR ATAXIAS; UBIQUINONE;

EID: 84978910632     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.07.005     Document Type: Article

References (78)

1. [1] Allen, S.P., Duffy, L.M., Shaw, P.J., Grierson, A.J., Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients. Neurobiol. Aging 36 (2015), 2893–2903.
2. [2] Ayala-Pena, S., Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radic. Biol. Med 62 (2013), 102–110.
3. [3] Beal, M.F., Mitochondria, free radicals, and neurodegeneration. Curr. Opin. Neurobiol. 6 (1996), 661–666.
4. [4] Brennan, W.A. Jr., Bird, E.D., Aprille, J.R., Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem 44 (1985), 1948–1950.
5. [5] Brown, S.A., Loew, L.M., Computational analysis of calcium signaling and membrane electrophysiology in cerebellar Purkinje neurons associated with ataxia. BMC Syst. Biol., 6, 2012, 70.
6. [6] Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D., Beal, M.F., Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41 (1997), 646–653.
7. [7] Burk, K., Abele, M., Fetter, M., Dichgans, J., Skalej, M., Laccone, F., Didierjean, O., Brice, A., Klockgether, T., Autosomal dominant cerebellar ataxia type I clinical features and MRI in families with SCA1, SCA2 and SCA3. Brain 119:Pt 5 (1996), 1497–1505.
8. [8] Burright, E.N., Clark, H.B., Servadio, A., Matilla, T., Feddersen, R.M., Yunis, W.S., Duvick, L.A., Zoghbi, H.Y., Orr, H.T., SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82 (1995), 937–948.
9. [9] Burte, F., Carelli, V., Chinnery, P.F., Yu-Wai-Man, P., Disturbed mitochondrial dynamics and neurodegenerative disorders. Nat. Rev. Neurol. 11 (2015), 11–24.
10. [10] Calabrese, V., Lodi, R., Tonon, C., D'Agata, V., Sapienza, M., Scapagnini, G., Mangiameli, A., Pennisi, G., Stella, A.M., Butterfield, D.A., Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233 (2005), 145–162.
11. [11] Calabrese, V., Scapagnini, G., Giuffrida Stella, A.M., Bates, T.E., Clark, J.B., Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem. Res. 26 (2001), 739–764.
12. [12] Chaturvedi, R.K., Flint Beal, M., Mitochondrial diseases of the brain. Free Radic. Biol. Med. 63 (2013), 1–29.
13. [13] Cozzolino, M., Ferri, A., Valle, C., Carri, M.T., Mitochondria and ALS: implications from novel genes and pathways. Mol. Cell Neurosci. 55 (2013), 44–49.
14. [14] Criscuolo, C., Procaccini, C., Meschini, M.C., Cianflone, A., Carbone, R., Doccini, S., Devos, D., Nesti, C., Vuillaume, I., Pellegrino, M., et al. Powerhouse failure and oxidative damage in autosomal recessive spastic ataxia of Charlevoix-Saguenay. J. Neurol. 262 (2015), 2755–2763.
15. [15] De Paepe, B., De Bleecker, J.L., Van Coster, R., Histochemical methods for the diagnosis of mitochondrial diseases. Curr. Protoc. Hum. Genet., 2009 (Chapter 19, Unit19 12).
16. [16] Deerinck, T.J., Bushong, E.A., Thor, A., Ellisman, M.H., NCMIR methods for 3D EM: a new protocol for preparation of biological specimens for serial block face scanning electron microscopy. Microscopy, 2010, 6–8.
17. [17] DiMauro, S., Schon, E.A., Mitochondrial disorders in the nervous system. Annu Rev. Neurosci. 31 (2008), 91–123.
18. [18] Duffy, L.M., Chapman, A.L., Shaw, P.J., Grierson, A.J., Review: the role of mitochondria in the pathogenesis of amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 37 (2011), 336–352.
19. [19] Emir, U.E., Brent Clark, H., Vollmers, M.L., Eberly, L.E., Oz, G., Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1. J. Neurochem. 127 (2013), 660–668.
20. [20] Fernandez-Funez, P., Nino-Rosales, M.L., de Gouyon, B., She, W.C., Luchak, J.M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P.J., et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408 (2000), 101–106.
21. [21] Friedland-Leuner, K., Stockburger, C., Denzer, I., Eckert, G.P., Muller, W.E., Mitochondrial dysfunction: cause and consequence of Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 127 (2014), 183–210.
22. [22] Gennarino, V.A., Singh, R.K., White, J.J., De Maio, A., Han, K., Kim, J.Y., Jafar-Nejad, P., di Ronza, A., Kang, H., Sayegh, L.S., et al. Pumilio1 haploinsufficiency leads to SCA1-like neurodegeneration by increasing wild-type Ataxin1 levels. Cell 160 (2015), 1087–1098.
23. [23] Ghosh, A., Chandran, K., Kalivendi, S.V., Joseph, J., Antholine, W.E., Hillard, C.J., Kanthasamy, A., Kanthasamy, A., Kalyanaraman, B., Neuroprotection by a mitochondria-targeted drug in a Parkinson's disease model. Free Radic. Biol. Med. 49 (2010), 1674–1684.
24. [24] Girard, M., Lariviere, R., Parfitt, D.A., Deane, E.C., Gaudet, R., Nossova, N., Blondeau, F., Prenosil, G., Vermeulen, E.G., Duchen, M.R., et al. Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS). Proc. Natl. Acad. Sci. USA 109 (2012), 1661–1666.
25. [25] Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M., Schapira, A.H., Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39 (1996), 385–389.
26. [26] Guedes-Dias, P., Pinho, B.R., Soares, T.R., de Proenca, J., Duchen, M.R., Oliveira, J.M., Mitochondrial dynamics and quality control in Huntington's disease. Neurobiol. Dis., 2015.
27. [27] Guerrini, L., Lolli, F., Ginestroni, A., Belli, G., Della Nave, R., Tessa, C., Foresti, S., Cosottini, M., Piacentini, S., Salvi, F., et al. Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 127 (2004), 1785–1795.
28. [28] Haelterman, N.A., Yoon, W.H., Sandoval, H., Jaiswal, M., Shulman, J.M., Bellen, H.J., A mitocentric view of Parkinson's disease. Annu. Rev. Neurosci. 37 (2014), 137–159.
29. [29] Halbach, M.V., Gispert, S., Stehning, T., Damrath, E., Walter, M., Auburger, G., Atxn2 knockout and CAG42-knock-in cerebellum shows similarly dysregulated expression in calcium homeostasis pathway. Cerebellum, 2016.
30. [30] Hang, L., Thundyil, J., Lim, K.L., Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection. Ann. N Y Acad. Sci. 1350 (2015), 37–47.
31. [31] Heller, M., Schlappritzi, E., Stalder, D., Nuoffer, J.M., Haeberli, A., Compositional protein analysis of high density lipoproteins in hypercholesterolemia by shotgun LC-MS/MS and probabilistic peptide scoring. Mol. Cell Proteom. 6 (2007), 1059–1072.
32. [32] Ingram, M., Wozniak, E.A., Duvick, L., Yang, R., Bergmann, P., Carson, R., O'Callaghan, B., Zoghbi, H.Y., Henzler, C., Orr, H.T., Cerebellar transcriptome profiles of ATXN1 transgenic mice reveal SCA1 disease progression and protection pathways. Neuron 89 (2016), 1194–1207.
33. [33] Ito, H., Fujita, K., Tagawa, K., Chen, X., Homma, H., Sasabe, T., Shimizu, J., Shimizu, S., Tamura, T., Muramatsu, S., et al. HMGB1 facilitates repair of mitochondrial DNA damage and extends the lifespan of mutant ataxin-1 knock-in mice. EMBO Mol. Med 7 (2015), 78–101.
34. [34] Jafar-Nejad, P., Ward, C.S., Richman, R., Orr, H.T., Zoghbi, H.Y., Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc. Natl. Acad. Sci. USA 108 (2011), 2142–2147.
35. [35] James, A.M., Sharpley, M.S., Manas, A.R., Frerman, F.E., Hirst, J., Smith, R.A., Murphy, M.P., Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem. 282 (2007), 14708–14718.
36. [36] Karbowski, M., Neutzner, A., Neurodegeneration as a consequence of failed mitochondrial maintenance. Acta Neuropathol. 123 (2012), 157–171.
37. [37] Karnes, H.E., Scaletty, P.N., Durham, D., Histochemical and fluorescent analyses of mitochondrial integrity in chick auditory neurons following deafferentation. J. Am. Acad. Audiol. 21 (2010), 204–218.
38. [38] Kasumu, A.W., Liang, X., Egorova, P., Vorontsova, D., Bezprozvanny, I., Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice. J. Neurosci.: J. Soc. Neurosci. 32 (2012), 12786–12796.
39. [39] Koeppen, A.H., The Purkinje cell and its afferents in human hereditary ataxia. J. Neuropathol. Exp. Neurol. 50 (1991), 505–514.
40. [40] Kremer, J.R., Mastronarde, D.N., McIntosh, J.R., Computer visualization of three-dimensional image data using IMOD. J. Struct. Biol. 116 (1996), 71–76.
41. [41] Labbadia, J., Morimoto, R.I., Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 38 (2013), 378–385.
42. [42] Lin, M.T., Beal, M.F., Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006), 787–795.
43. [43] Magrane, J., Manfredi, G., Mitochondrial function, morphology, and axonal transport in amyotrophic lateral sclerosis. Antioxid. Redox Signal 11 (2009), 1615–1626.
44. [44] Mahler, A., Steiniger, J., Endres, M., Paul, F., Boschmann, M., Doss, S., Increased catabolic state in spinocerebellar ataxia type 1 patients. Cerebellum 13 (2014), 440–446.
45. [45] Manfredi, G., Beal, M.F., The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol. 10 (2000), 462–472.
46. [46] McManus, M.J., Murphy, M.P., Franklin, J.L., The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J. Neurosci.: J. Soc. Neurosci. 31 (2011), 15703–15715.
47. [47] Miquel, E., Cassina, A., Martinez-Palma, L., Souza, J.M., Bolatto, C., Rodriguez-Bottero, S., Logan, A., Smith, R.A., Murphy, M.P., Barbeito, L., et al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med. 70 (2014), 204–213.
48. [48] Moffett, J.R., Arun, P., Ariyannur, P.S., Namboodiri, A.M., N-Acetylaspartate reductions in brain injury: impact on post-injury neuroenergetics, lipid synthesis, and protein acetylation. Front. Neuroenergetics, 5, 2013, 11.
49. [49] Orr, H.T., Cell biology of spinocerebellar ataxia. J. Cell Biol. 197 (2012), 167–177.
50. [50] Overk, C.R., Masliah, E., Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem. Pharmacol. 88 (2014), 508–516.
51. [51] Oz, G., Nelson, C.D., Koski, D.M., Henry, P.G., Marjanska, M., Deelchand, D.K., Shanley, R., Eberly, L.E., Orr, H.T., Clark, H.B., Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci.: J. Soc. Neurosci. 30 (2010), 3831–3838.
52. [52] Pellistri, F., Bucciantini, M., Invernizzi, G., Gatta, E., Penco, A., Frana, A.M., Nosi, D., Relini, A., Regonesi, M.E., Gliozzi, A., et al. Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells. Biochim. Biophys. Acta 1833 (2013), 3155–3165.
53. [53] Peng, T.I., Jou, M.J., Oxidative stress caused by mitochondrial calcium overload. Ann. N Y Acad. Sci. 1201 (2010), 183–188.
54. [54] Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin, T.E., UCSF Chimera–a visualization system for exploratory research and analysis. J. Comput. Chem. 25 (2004), 1605–1612.
55. [55] Rodriguez-Cuenca, S., Cocheme, H.M., Logan, A., Abakumova, I., Prime, T.A., Rose, C., Vidal-Puig, A., Smith, A.C., Rubinsztein, D.C., Fearnley, I.M., et al. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic. Biol. Med 48 (2010), 161–172.
56. [56] Ross, J.M., Visualization of mitochondrial respiratory function using cytochrome c oxidase/succinate dehydrogenase (COX/SDH) double-labeling histochemistry. J. Vis. Exp., 2011, e3266.
57. [57] Ruegsegger, C., Stucki, D.M., Steiner, S., Angliker, N., Radecke, J., Keller, E., Zuber, B., Ruegg, M.A., Saxena, S., Impaired mTORC1-dependent expression of Homer-3 influences SCA1 pathophysiology. Neuron 89 (2016), 129–146.
58. [58] Ruffoli, R., Bartalucci, A., Frati, A., Fornai, F., Ultrastructural studies of ALS mitochondria connect altered function and permeability with defects of mitophagy and mitochondriogenesis. Front. Cell Neurosci., 9, 2015, 341.
59. [59] Ryan, B.J., Hoek, S., Fon, E.A., Wade-Martins, R., Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem. Sci. 40 (2015), 200–210.
60. [60] Schapira, A.H., Oxidative stress and mitochondrial dysfunction in neurodegeneration. Curr. Opin. Neurol. 9 (1996), 260–264.
61. [61] Schapira, A.H., Mitochondrial dysfunction in neurodegenerative disorders. Biochim. Biophys. Acta 1366 (1998), 225–233.
62. [62] Serra, H.G., Byam, C.E., Lande, J.D., Tousey, S.K., Zoghbi, H.Y., Orr, H.T., Gene profiling links SCA1 pathophysiology to glutamate signaling in Purkinje cells of transgenic mice. Hum. Mol. Genet. 13 (2004), 2535–2543.
63. [63] Signoretti, S., Marmarou, A., Aygok, G.A., Fatouros, P.P., Portella, G., Bullock, R.M., Assessment of mitochondrial impairment in traumatic brain injury using high-resolution proton magnetic resonance spectroscopy. J. Neurosurg. 108 (2008), 42–52.
64. [64] Simon, D.K., Zheng, K., Velazquez, L., Santos, N., Almaguer, L., Figueroa, K.P., Pulst, S.M., Mitochondrial complex I gene variant associated with early age at onset in spinocerebellar ataxia type 2. Arch. Neurol. 64 (2007), 1042–1044.
65. [65] Simoncini, C., Orsucci, D., Caldarazzo Ienco, E., Siciliano, G., Bonuccelli, U., Mancuso, M., Alzheimer's pathogenesis and its link to the mitochondrion. Oxid Med. Cell Longev., 2015, 2015, 803942.
66. [66] Smith, R.A., Murphy, M.P., Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. N Y Acad. Sci. 1201 (2010), 96–103.
67. [67] Snow, B.J., Rolfe, F.L., Lockhart, M.M., Frampton, C.M., O'Sullivan, J.D., Fung, V., Smith, R.A., Murphy, M.P., Taylor, K.M., Protect Study, G., A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord. 25 (2010), 1670–1674.
68. [68] Tatsuta, T., Langer, T., Quality control of mitochondria: protection against neurodegeneration and ageing. EMBO J. 27 (2008), 306–314.
69. [69] Travacio, M., Maria Polo, J., Llesuy, S., Chromium(VI) induces oxidative stress in the mouse brain. Toxicology 150 (2000), 137–146.
70. [70] Tsunemi, T., La Spada, A.R., PGC-1alpha at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond. Prog. Neurobiol. 97 (2012), 142–151.
71. [71] Wang, L., Yang, X., Shen, Y., Molecular mechanism of mitochondrial calcium uptake. Cell. Mol. Life Sci.: CMLS 72 (2015), 1489–1498.
72. [72] Wang, Y.C., Lee, C.M., Lee, L.C., Tung, L.C., Hsieh-Li, H.M., Lee-Chen, G.J., Su, M.T., Mitochondrial dysfunction and oxidative stress contribute to the pathogenesis of spinocerebellar ataxia type 12 (SCA12). J. Biol. Chem. 286 (2011), 21742–21754.
73. [73] Watase, K., Weeber, E.J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D.L., et al. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34 (2002), 905–919.
74. [74] Yu, Y.C., Kuo, C.L., Cheng, W.L., Liu, C.S., Hsieh, M., Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease. J. Neurosci. Res. 87 (2009), 1884–1891.
75. [75] Zeviani, M., Simonati, A., Bindoff, L.A., Ataxia in mitochondrial disorders. Handb. Clin. Neurol. 103 (2012), 359–372.
76. [76] Zoghbi, H.Y., Analysis of the CAG repeat and gene product in spinocerebellar ataxia type 1. Proc. Assoc. Am. Physicians 107 (1995), 231–236.
77. [77] Zoghbi, H.Y., Orr, H.T., Spinocerebellar ataxia type 1. Semin. Cell Biol. 6 (1995), 29–35.
78. [78] Zoghbi, H.Y., Orr, H.T., Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J. Biol. Chem. 284 (2009), 7425–7429.